Upadacitinib induction therapy in Crohn’ s disease: a retrospective real-world study in biologic-refractory patients
This real-world study demonstrates that upadacitinib is effective and generally well tolerated in biologic-experienced Chinese patients with active CD. Our findings support the clinical utility of JAK1 inhibition in a real-world setting.
Authors
- Liangru Zhu (ORCID: https://orcid.org/0000-0002-7372-294X)
- Rong Lin (ORCID: https://orcid.org/0000-0001-9463-8942)
- Yu Fu (ORCID: https://orcid.org/0000-0002-2413-3858)
- Yu Qi (ORCID: https://orcid.org/0000-0003-2204-1420)
- Huan Wang (ORCID: https://orcid.org/0000-0002-3816-9552)
- Fang Liu (ORCID: https://orcid.org/0000-0002-0874-6267)
- Yidong Chen (ORCID: https://orcid.org/0000-0002-7866-7628)
- Jiamin Li (ORCID: https://orcid.org/0000-0002-5352-2828)
- Xiaoyu Fu
- Qian Xia (ORCID: https://orcid.org/0000-0002-7786-3336)
- Lei Tu (ORCID: https://orcid.org/0000-0002-1475-2858)
- Yiyu Cheng (ORCID: https://orcid.org/0000-0003-1423-162X)
- Xiao‐Peng Zhang (ORCID: https://orcid.org/0000-0001-8170-1236)
Institutions
- First Affiliated Hospital of Shihezi University Medical College (CN)
- Union Hospital (CN)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1186/s12876-025-04305-z
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00